Collegeville, PA, United States of America

Duke M Fitch

This inventor holds 8 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Glaxosmithkline LLC. Active years: 2010-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Duke M Fitch. Retrieved from https://idiyas.com/inventor/duke-m-fitch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 9)

% Patents Active = 75.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 54(Granted Patents)

Company Filing History:

8 out of 358

Glaxosmithkline LLC

patents

Years Active: 2010-2023

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11643397 - Prolyl hydroxylase inhibitors (2023-05-09),

2. 10336711 - Prolyl hydroxylase inhibitors (2019-07-02),

3. 10035779 - Prolyl hydroxylase inhibitors (2018-07-31),

4. 8815884 - Prolyl hydroxylase inhibitors (2014-08-26),

5. 8557834 - Prolyl hydroxylase inhibitors (2013-10-15),

6. 8324208 - Prolyl hydroxylase inhibitors (2012-12-04),

7. 7897612 - Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors (2011-03-01),

8. 7674792 - 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one (2010-03-09),

Title: Duke M Fitch: Innovator in Prolyl Hydroxylase Inhibitors

Introduction

Duke M Fitch is a prominent inventor based in Collegeville, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of prolyl hydroxylase inhibitors. With a total of 8 patents to his name, Fitch's work has the potential to impact the treatment of various diseases.

Latest Patents

Fitch's latest patents focus on prolyl hydroxylase inhibitors. The inventions described relate to certain pyrimidinetrione N-substituted glycine derivatives, which act as antagonists of HIF prolyl hydroxylases. These compounds are particularly useful for treating diseases that benefit from the inhibition of this enzyme, with anemia being a notable example.

Career Highlights

Duke M Fitch has established himself as a key figure in the pharmaceutical industry. He is currently associated with GlaxoSmithKline LLC, where he continues to innovate and develop new therapeutic solutions. His expertise in the field has led to advancements that could change the landscape of treatment options available for patients.

Collaborations

Fitch has worked alongside notable colleagues such as Antony N Shaw and Kenneth Wiggall. Their collaborative efforts have contributed to the success of various projects and innovations within the company.

Conclusion

Duke M Fitch's contributions to the field of prolyl hydroxylase inhibitors highlight his role as an influential inventor. His work not only showcases his innovative spirit but also emphasizes the importance of collaboration in advancing medical science.

Profile summary based on public USPTO records.